Now Approved CRYSVITA (burosumab-twza) for X-linked Hypophosphatemia (XLH)
injection for subcutaneous use
The first and only FDA-approved therapy for X-linked hypophosphatemia (XLH)
- CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of XLH in adult and pediatric patients 1 year of age and older.
- CRYSVITA is the only therapy that addresses the underlying cause of XLH.